Sniecinski Megan 4/A
4/A · BIOCRYST PHARMACEUTICALS INC · Filed Dec 26, 2019
Insider Transaction Report
Form 4/AAmended
Sniecinski Megan
Chief Business Officer
Transactions
- Award
Emp. Stock Option (Right to Buy)
2019-12-17+240,000→ 240,000 totalExercise: $3.23From: 2020-12-17Exp: 2029-12-17→ Common Stock (240,000 underlying)
Footnotes (1)
- [F1]Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.